> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Bio-Rad Posts $458.6 Million Profit On Sartorius Gain, Yet Its Operations Lost $49.7 Million
- URL: https://www.bullished.co/bio-rad-posts-458-6-million-profit-on-sartorius-gain-yet-its-operations-lost-49-7-million-9d58e426/
- Published: 2026-11-04T22:44:11.000Z
- Updated: 2026-11-04T22:44:11.000Z
- Description: Restructuring and a roughly $50 million impairment drove the operating loss, while adjusted margin widened to 12.8% and the 2026 outlook held.
- Author: Matteo Parrino
- Tags: SEC Filings, BIO, Industry: Healthcare

Bio-Rad Laboratories, which makes instruments and test kits for life science research and clinical diagnostics, reported [net income of $458.6 million](https://www.sec.gov/Archives/edgar/data/0000012208/000001220826000057/bio-8k1142026xex991.htm?ref=bullished.co) for the third quarter, or $17.02 a diluted share, against a $341.9 million loss a year earlier. The profit came mostly from a change in the fair market value of its Sartorius AG investment, while the business itself lost $49.7 million from operations, the company said Wednesday.

## A profit built on an investment

The company booked a $588.2 million gain from the change in fair market value of equity securities and a loan receivable, versus a $495.3 million loss in the third quarter of 2025\. It said the Sartorius change substantially contributed to the bottom line.

Operations told a different story. Standard-accounting operating results swung to a $49.7 million loss, a negative 7.6% margin, from $65.3 million of operating income a year earlier. Restructuring charges of about $77 million and a non-cash impairment of about $50 million on purchased intangibles, tied to discontinued and reprioritized R&D programs, drove the drop, according to the [earnings presentation](https://www.sec.gov/Archives/edgar/data/0000012208/000001220826000057/a3q26earningspresentatio.htm?ref=bullished.co). Gross margin fell to 50.1% from 52.6%.

## Adjusted margins widen, sales turn up

Excluding those items, adjusted operating income rose to $83.7 million from $77.0 million, and the adjusted operating margin reached 12.8% from 11.8%. Adjusted earnings were [$2.65 a diluted share](https://www.businesswire.com/news/home/20261104537666/en/Bio-Rad-Reports-Third-Quarter-2026-Financial-Results?ref=bullished.co), up from $2.26\. Free cash flow was $65.2 million, down from $89.2 million.

[Sales edged up 0.5%](https://www.businesswire.com/news/home/20261104537666/en/Bio-Rad-Reports-Third-Quarter-2026-Financial-Results?ref=bullished.co) to $656.4 million, or 0.7% on a currency-neutral basis. Clinical Diagnostics, which sells test systems and kits to hospital and reference labs, rose 2.7% to $401.8 million, led by quality systems and diabetes products.

Life Science slipped 2.8% to $254.6 million, or 2.4% currency-neutral, on lower process chromatography sales and a weak academic research market. Droplet Digital PCR sales rose, with the instrument line up more than 20%, the presentation said.

CEO Norman Schwartz said the company "returned to currency-neutral revenue growth" and that progress "gives us confidence in our 2026 outlook."

## Outlook unchanged, next stop UBS

Bio-Rad kept its 2026 forecast: adjusted currency-neutral revenue from a decline of about 3.0% to growth of about 0.5%, and an adjusted operating margin of about 10.0% to 12.0%.

CFO Roop Lakkaraju is scheduled to take part in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 10, at 8:00 a.m. Eastern, [the company said](https://finance.yahoo.com/healthcare/articles/bio-rad-participate-fireside-chat-203000215.html?ref=bullished.co).

Management discussed the results on a call at 5:00 p.m. Eastern on Wednesday, with the UBS appearance next.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — BIO-RAD LABORATORIES, INC. (BIO)](https://www.sec.gov/Archives/edgar/data/0000012208/000001220826000057/bio-20261104.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit bio-8k1142026xex991.htm — BIO-RAD LABORATORIES, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000012208/000001220826000057/bio-8k1142026xex991.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit a3q26earningspresentatio.htm — BIO-RAD LABORATORIES, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000012208/000001220826000057/a3q26earningspresentatio.htm?ref=bullished.co) — SEC EDGAR
- [Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference](https://finance.yahoo.com/healthcare/articles/bio-rad-participate-fireside-chat-203000215.html?ref=bullished.co) — Yahoo Finance
- [Bio-Rad Reports Third-Quarter 2026 Financial Results](https://www.businesswire.com/news/home/20261104537666/en/Bio-Rad-Reports-Third-Quarter-2026-Financial-Results?ref=bullished.co) — businesswire.com